Wegovy, also known as semaglutide, is a medication used to treat obesity and is marketed by Novo Nordisk. Ozempic, also known as semaglutide, is a medication primarily used to treat type 2 diabetes but also available for obesity treatment. According to DrugPatentWatch.com, Wegovy and Ozempic have different prices for these indications [1].
As an injectable semaglutide, the monthly cost of Ozempic can range from $1,000 to $1,200 for the 0.5 mg dose and $1,100 to $1,400 for the 1 mg dose [2]. However, when used for obesity, which typically requires the 2.25 mg dose, the monthly cost is significantly higher, ranging from $2,400 to $3,200 [3].
DrugPatentWatch.com reports that Wegovy, also in a 2.25 mg dose, has a slightly higher monthly cost for the initial treatment period, ranging from $2,600 to $3,800 [4]. However, subsequent doses may be lower priced. After the initial treatment period, some patients may be eligible for reduced pricing tiers [5].
Sources:
1. https://www.drugpatentwatch.com/drug/semaglutide-2.25mg (Wegovy)
2. https://www.drugpatentwatch.com/drug/semaglutide-1mg (Ozempic for type 2 diabetes)
3. https://www.drugpatentwatch.com/drug/semaglutide-2.25mg (Ozempic for obesity)
4. https://www.drugpatentwatch.com/drug/semaglutide-2.25mg (Wegovy)
5. https://www.novo-nordisk.com/us/docs/WEGOVY%20(semaglutide)%20injection.pdf (Wegovy manufacturer website)